| Name | Title | Contact Details |
|---|
At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.
Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.) is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers (bedsores).
Star X-Ray Co. is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VisCardia Inc is a privately held medical device company in Portland Oregon developing a novel chronic heart failure therapy. Our proprietary implantable system uses the patient’s own thoracic musculature to improve cardiac filling and output.
ACUFOCUS, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.